Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:44:59 EST Fri 09 Jan 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.1119.99·120.488.4120.674.647265    128.70  88.57509:25:12Dec 2215 min RT 2¢

Recent Trades - Last 10 of 65
Time ETExPriceChangeVolume
09:25:12Q120.48-0.19100
09:25:10Q120.0826-0.58741
09:25:01Q120.730.061
09:25:00Q120.43-0.24100
09:25:00Q120.43-0.2474
09:25:00Q120.43-0.2422
09:24:46Q120.31-0.366
09:21:55Q120.4777-0.19231
09:17:02Q120.48-0.191
09:13:32Q120.50-0.17115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-22 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conference
2025-12-22 08:00U:GILDNews ReleaseGilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
2025-12-19 14:21U:GILDNews ReleaseGilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
2025-12-18 08:30U:GILDNews ReleaseGilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
2025-12-15 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
2025-12-12 10:31U:GILDNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-12-09 08:30U:GILDNews ReleaseGilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
2025-12-07 08:00U:GILDNews ReleaseYescarta(TM) Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
2025-12-06 14:00U:GILDNews ReleaseKite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
2025-11-24 08:30U:GILDNews ReleaseGilead Foundation Commits Over $3 Million to Address Food Insecurity
2025-11-20 07:02U:GILDNews ReleaseAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
2025-11-18 05:00U:GILDNews ReleaseGilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
2025-11-13 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
2025-11-07 08:30U:GILDNews ReleaseGilead Provides Update on Phase 3 ASCENT-07 Study
2025-11-07 08:00U:GILDNews ReleaseGilead's Livdelzi(TM) Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
2025-11-04 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-11-03 09:10U:GILDNews ReleaseGilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
2025-10-31 08:00U:GILDNews ReleaseGilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo(TM) (Lenacapavir)
2025-10-30 16:02U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2025 Financial Results